| abstract |
The present invention relates generally to bis-amide groups, including pharmaceuticals, especially polycyclic bis-amide MMP-13 inhibiting compounds. More particularly, the present invention includes pyrimidinyl bis-amide groups in combination with polycyclic moieties that exhibit increased efficacy and solubility relative to known bis-amide groups including MMP-13 inhibitors. Provide a new class of MMP-13 inhibitor compounds. |